NewsBenzingaHC Wainwright & Co. mantiene il rating Buy su Revolution Medicines, alza il prezzo obiettivo a 350 dollari. HC Wainwright & Co. mantiene il rating Buy su Revolution Medicines, alza il prezzo obiettivo a 350 dollari. Benzinga 2026.11.06 12:13 (GMT+0) Open on Benzinga Other news Piper Sandler Maintains Overweight on ICU Medical, Raises Price Target to $200 Keybanc Maintains Overweight on Five9, Raises Price Target to $34 Piper Sandler Maintains Neutral on Collegium Pharmaceutical, Lowers Price Target to $28 Keybanc Maintains Overweight on FIGS, Raises Price Target to $27 Reported Earlier, Kazakhstan Says Oil Exports To Germany Won't Resume By End Of 2026 Piper Sandler Maintains Neutral on Becton Dickinson, Raises Price Target to $200
